Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) posted quarterly Net Cash Flow of -$246.0 million for Q1 2026, down 436.61% year-over-year from $73.1 million in Q1 2025, and down 210.75% quarter-over-quarter from $222.1 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) Net Cash Flow (2013 - 2026) Analysis & Trends
Ultragenyx Pharmaceutical (RARE) has reported Net Cash Flow for 14 consecutive years, with -$246.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Cash Flow fell 436.61% year-over-year to -$246.0 million; the TTM figure through Mar 2026 stood at $47.8 million (up 173.28% YoY), while the FY2025 annual figure was $248.0 million, up 851.52% from the prior year.
- Net Cash Flow declined to -$246.0 million in Q1 2026 per RARE's latest filing, from $222.1 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $368.5 million in Q2 2024 and bottomed at -$331.3 million in Q3 2024.
- Historically, Net Cash Flow has averaged -$7.1 million across 5 years, with a median of $7.7 million in 2022.
- On a YoY basis, Net Cash Flow climbed as much as 2164.18% in 2024 and fell as far as 1068.89% in 2024.
- Ultragenyx Pharmaceutical's Net Cash Flow stood at -$260.1 million in 2022, then soared by 153.59% to $139.4 million in 2023, then plunged by 81.25% to $26.1 million in 2024, then soared by 749.94% to $222.1 million in 2025, then plunged by 210.75% to -$246.0 million in 2026.
- Business Quant data shows RARE's Net Cash Flow at -$246.0 million in Q1 2026, $222.1 million in Q4 2025, and $25.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.61 Bn | 2.33 Bn | 180.00 Mn | -53.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -53.00 Mn |
| Jun 30, 2026 | -53.00 Mn |
| Mar 31, 2026 | -246.00 Mn |
| Mar 31, 2026 | -246.00 Mn |
| Dec 31, 2025 | 222.12 Mn |
| Dec 31, 2025 | 222.12 Mn |
| Sep 30, 2025 | 25.76 Mn |
| Sep 30, 2025 | 25.76 Mn |
| Jun 30, 2025 | 45.97 Mn |
| Jun 30, 2025 | 45.97 Mn |
| Mar 31, 2025 | -45.84 Mn |
| Mar 31, 2025 | -45.84 Mn |
| Dec 31, 2024 | 26.13 Mn |
| Dec 31, 2024 | 26.13 Mn |
| Sep 30, 2024 | -331.32 Mn |
| Sep 30, 2024 | -331.32 Mn |
| Jun 30, 2024 | 368.54 Mn |
| Jun 30, 2024 | 368.54 Mn |
| Mar 31, 2024 | -96.35 Mn |
| Mar 31, 2024 | -96.35 Mn |